A Randomized Controlled Trial of Mindfulness-Based Cognitive Therapy for Treatment-Resistant Depression

Area of Science:

• Psychiatry
• Clinical Psychology
• Behavioral Medicine

Background:

• Treatment-resistant depression (TRD) presents significant clinical challenges.
• Mindfulness-Based Cognitive Therapy (MBCT) is explored as an adjunct treatment.
• Standard pharmacotherapy (TAU) is the current baseline treatment.

Purpose of the Study:

• To evaluate the efficacy of MBCT as an adjunct to TAU pharmacotherapy in TRD.
• To compare MBCT with a structurally equivalent active comparison (Health Enhancement Program - HEP).

Main Methods:

• A single-site randomized controlled trial (RCT) was conducted.
• 173 adult outpatients with TRD were enrolled.
• An 8-week course of MBCT or HEP was compared as an adjunct to TAU pharmacotherapy.
• The primary outcome was the change in depression severity (Hamilton Depression Rating Scale - HAM-D17).
• Secondary outcomes included treatment response and remission rates.

Main Results:

• MBCT showed a significantly greater mean percent reduction in HAM-D17 scores compared to HEP (36.6% vs. 25.3%, p=0.01).
• Treatment response rates were significantly higher in the MBCT group (30.3% vs. 15.3%, p=0.03).
• Remission rates did not significantly differ between MBCT and HEP (22.4% vs. 13.9%, p=0.15).
• State anxiety, perceived stress, and personality disorder negatively impacted outcomes.

Conclusions:

• MBCT significantly decreased depression severity and improved treatment response rates at 8 weeks in TRD patients.
• MBCT is a viable adjunctive therapy for managing treatment-resistant depression.
• Further research may explore factors influencing remission rates.